Human Hepatocyte Growth Factor Receptor (MET) Protein

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
Description
Human Hepatocyte Growth Factor Receptor (MET) Protein is a recombinant Human protein produced in a Mammalian cell expression system.
Documents del producto
Product specifications
Category | Proteins and Peptides |
Immunogen Target | Hepatocyte Growth Factor Receptor (MET) |
Host | Mammalian cells |
Origin | Human |
Conjugation | Unconjugated |
Observed MW | Molecular Weight: Calculated MW: 105.10 kDa Sequence Fragment: Met1-Thr932 Tag: C-terminal His tag |
Expression | Recombinant |
Purity | > 90% (SDS-PAGE) |
Size 1 | 100 µg |
Size 2 | 1 mg |
Form | Lyophilized Reconstitute in sterile water to produce a stock solution. |
Tested Applications | ELISA, WB, SDS-PAGE |
Buffer | Prior to lyophilization: PBS pH 7.4, 1 mM EDTA, 4% Trehalose, 1% Mannitol. |
Availability | Shipped within 5-12 working days. |
Storage | Store at 2-8 °C if the entire vial will be used within 1 week. Aliquot and store at -20 °C for long-term storage. Avoid repeated freeze-thaw cycles. |
Dry Ice | No |
UniProt ID | P08581 |
Background | Protein MET |
Note | This product is for research use only. This product is shipped with ice packs. Not for human consumption, cosmetic, therapeutic or diagnostic use. |
Descripción
Related Products

MET antibody
c-Met(also named as MET or HGFR) is a receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. c-Met regulates many physiological processes including proliferation, scattering, morphogenesis and survival. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. Overexpression and/or mutation of c-Met has been reported in various human malignancies, including lung cancer, breast cancer, head and neck cancer, gastric cancer, colorectal cancer, bladder cancer, uterine cervix carcinoma, and esophageal carcinoma, c-Met could serve as an important therapeutic target(PMID: 26036285). This antibody recognizes the N-term of c-Met.
Ver Producto
MET antibody
Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. Ligand binding at the cell surface induces autophosphorylation of MET on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. The RAS-ERK activation is associated with the morphogenetic effects while PI3K/AKT coordinates prosurvival effects. During embryonic development, MET signaling plays a role in gastrulation, development and migration of muscles and neuronal precursors, angiogenesis and kidney formation. In adults, participates in wound healing as well as organ regeneration and tissue remodeling. Promotes also differentiation and proliferation of hematopoietic cells. May regulate cortical bone osteogenesis(By similarity). Acts as a receptor for Listeria internalin inlB, mediating entry of the pathogen into cells.
Ver Producto